Ipsen: Half-Year Statement of Ipsen's Liquidity Contract

PARIS, France--(Business Wire)--Regulatory News:

Ipsen (Paris:IPN)

As of December 31, 2007, as per the liquidity contract implemented
with NATIXIS SECURITIES the following assets appeared on the liquidity
account :

-- 21,986 shares

-- 2,147,085.85 EUR

As a remminder, as of the implementation date of the liquidity
contract, the following assets appeared on the liquidity account :

-- 1,238,932.41 EUR

-- 47,473 shares

About Ipsen

Ipsen is an innovation driven international specialty
pharmaceutical group with over 20 products on the market and a total
worldwide staff of nearly 4,000. The company's development strategy is
based on a combination of products in targeted therapeutic areas
(oncology, endocrinology and neuromuscular disorders) which are growth
drivers, and primary care products which contribute significantly to
its research financing. This strategy is also supported by an active
policy of partnerships. The location of its four Research and
Development centres (Paris, Boston, Barcelona, London) gives the Group
a competitive edge in gaining access to leading university research
teams and highly qualified personnel. In 2006, R&D expenditure was EUR
178.3 million, i.e. 20.7% of consolidated sales, which amounted to EUR
861.7 million while total revenues amounted to EUR 945.3 million (in
IFRS). 700 people in R&D are dedicated to the discovery and
development of innovative drugs for patient care. Ipsen's shares are
traded on Segment A of Eurolist by EuronextTM (stock code: IPN, ISIN
code: FR0010259150). Ipsen' s shares are eligible to the "Service de
Règlement Différé" ("SRD") and the Group is part of the SBF 250 index.
From 24 December 2007, the Group will be part of the SBF120 index. For
more information on Ipsen, visit our website at www.ipsen.com.

Forward-looking statements

The forward-looking statements and targets contained herein are
based on Ipsen's management's current views and assumptions. Such
statements involve known and unknown risks and uncertainties that may
cause actual results, performance or events to differ materially from
those anticipated herein. Moreover, the Research and Development
process involves several stages at each of which there is a
substantial risk that the Group will fail to achieve its objectives
and be forced to abandon its efforts in respect of a product in which
it has invested significant sums. Therefore, the Group cannot be
certain that favourable results obtained during pre-clinical trials
will be confirmed subsequently during clinical trials, or that the
results of clinical trials will be sufficient to demonstrate the safe
and effective nature of the product concerned, or that the regulatory
authorities will be satisfied with the data and information provided
by the Company. Ipsen expressly disclaims any obligation or
undertaking to update or revise any forward looking statements,
targets or estimates contained in this press release to reflect any
change in events, conditions, assumptions or circumstances on which
any such statements are based, unless so required by applicable law.
Ipsen's business is subject to the risk factors outlined in its
information documents filed with the French Autorité des Marchés
Financiers.

IPSEN
Didier Véron,
Directeur des Affaires Publiques et de la Communication
Tél.: +33 (0)1 44 30 42 38
Fax: +33 (0)1 44 30 42 04
e-mail: didier.veron@ipsen.com
or
David Schilansky,
Directeur des Relations Investisseurs
Tél.: +33 (0)1 44 30 43 31
Fax: +33 (0)1 44 30 43 21
e-mail: david.schilansky@ipsen.com

Copyright Business Wire 2008